Short commentary from Dr. Martin Abrahamson on using SGLT2 inhibitors for cardiovascular and renal disease with type 2 diabetes, from CCO
CME commentary: GLP-1 receptor agonists and weight reduction in diabetes. Evidence for exenatide, dulaglutide, liraglutide, semaglutide in T2D and obesity.
Expert recommendations from Clinical Care Options on using oral semaglutide to treat type 2 diabetes
Concise CCO expert commentary on potential side effects with GLP-1 receptor agonists in patients with type 2 diabetes